Clostridium Difficile Infections
Cancer center’s anti-COVID efforts reduced nosocomial infections
Enhanced infection prevention and control efforts during COVID-19 reduced the rates of some hospital infections at a comprehensive cancer center, including Clostridioides difficile and multidrug-resistant infections, according to a study.
Live biotherapeutics may be paradigm shift in C. difficile GIs have been waiting for
Nearly half a million Americans are diagnosed with Clostridioides difficile infection each year. Although often treated with antibiotics, C. difficile recurrence is possible. However, recently developed therapies may change this paradigm.
VIDEO: ‘Distinctive shift’ in gut microbiota after Rebyota treatment for C. difficile
CHICAGO — In a Healio video exclusive, Ken Blount, PhD, discusses successful restoration of gut microbiota and clonal engraftment as soon as 1 week after treatment with Rebyota in those with recurrent Clostridioides difficile infection.
FDA approves fecal microbiota biotherapeutic for recurrent C. difficile infection
The FDA has approved Rebyota, a microbiota-based live biotherapeutic indicated for the prevention of recurrent Clostridioides difficile infection in adults after antibiotic treatment, Ferring Pharmaceuticals announced in a press release.